Surufatinib clinical trials
Surufatinib is named as an intervention in 24 current clinical trials in our China register. 13 are recruiting patients now. The most common phase is Phase 2. The sponsor with the most trials is Sun Yat-sen University (6). The most-studied condition is Neuroendocrine Tumors.
How Surufatinib works
All drug targets →- Fibroblast growth factor receptor 1 inhibitor InhibitorTarget: FGFR1 fibroblast growth factor receptor 1✓ In ChEMBL and the Guide to Pharmacology
- Vascular endothelial growth factor receptor inhibitor InhibitorTarget: Vascular endothelial growth factor receptor✓ In ChEMBL and the Guide to Pharmacology
- Malignant pancreatic neoplasmPhase 3
- Neuroendocrine carcinomaPhase 3
- Neuroendocrine neoplasmPhase 3
- Pancreatic neoplasmPhase 3
- Pancreatic neuroendocrine tumorPhase 3
- Biliary tract cancerPhase 2/3
- Rectal cancerPhase 2/3
- Bile duct adenocarcinomaPhase 2
- Breast cancerPhase 2
- CancerPhase 2
Mechanisms and diseases from ChEMBL via the Open Targets Platform (release 26.09), ChEMBL record CHEMBL4297190, CC BY-SA 3.0. Targets checked against the IUPHAR/BPS Guide to PHARMACOLOGY (2026.3.1), ligand 9769, CC BY-SA 4.0. Trial phases are not approvals: approved uses are shown from the regulators' own records where we hold them.
Patient leaflets for Surufatinib
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
- UKUnited Kingdom: Search MHRA ProductsPatient information leaflets and SmPCs for UK-licensed products.
- USUnited States: Search DailyMedFDA-approved labels, including patient and medication guides.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
Trials by status
Trials by phase
Clinical trials of Surufatinib
24 trialsRegisters list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Conditions studied with Surufatinib
33 conditionsAll 33 conditions
| Condition (as registered) | Trials |
|---|---|
| Neuroendocrine Tumors | 3 |
| Pancreatic Cancer | 2 |
| Pancreatic Neoplasms | 2 |
| Pancreas Cancer | 2 |
| Ovarian Cancer | 2 |
| Gastric Cancer | 2 |
| Pancreatic Cancer Non-resectable | 1 |
| Pancreatic Ductal Adenocarcinoma, PDAC | 1 |
| Neuroendocrine Neoplasms | 1 |
| Sarcoma | 1 |
| Adenocarcinoma of Small Intestine | 1 |
| Appendix Carcinoma | 1 |
| Metastatic | 1 |
| Neuroendocrine Neoplasm | 1 |
| NSCLC (Non-small Cell Lung Cancer) | 1 |
| Intrahepatic Cholangiocarcinoma | 1 |
| PDAC - Pancreatic Ductal Adenocarcinoma | 1 |
| Borderline Resectable Pancreatic Cancer | 1 |
| High-Risk Resectable Pancreatic Cancer | 1 |
| Advanced Biliary Tract Cancer | 1 |
| Pancreatic Cancer, Adult | 1 |
| Surufatinib | 1 |
| Tislelizumab | 1 |
| Concurrent Chemoradiotherapy | 1 |
| Consolidation Therapy | 1 |
| Pulmonary Neuroendocrine Tumor | 1 |
| ESCC | 1 |
| Biliary Tract Cancer | 1 |
| Gastro Esophageal Junction Cancer | 1 |
| Advanced Non-Small Cell Lung Cancer | 1 |
| High-Risk Localized Soft Tissue Sarcoma | 1 |
| Pancreatic Cancer Resectable | 1 |
| Metastatic Pancreatic Cancer | 1 |
Sponsors
lead sponsor per trial+ 2 more sponsors in the trial list above.
By country register
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 24 | 13 |
A trial with sites in more than one country appears in each of those registers.
Related compounds
Questions about Surufatinib trials
How many clinical trials are testing Surufatinib?
24 current trials in our China register name Surufatinib (also registered as HMPL-012) as a drug or biological intervention, as of the registry sync on 10 November 2026. Completed and withdrawn studies are not counted.
Are Surufatinib trials recruiting patients?
Yes. 13 of the 24 trials are recruiting: 13 with sites in China. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Who sponsors Surufatinib clinical trials?
Sun Yat-sen University (6), Shanghai Zhongshan Hospital (2), Fudan University (2) and Union Hospital, Tongji Medical College, Huazhong University of Science and Technology (1), among 17 lead sponsors in total. The number in brackets is how many trials each organisation leads.
Where does this information come from?
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Surufatinib works or whether it is effective, and it is not medical advice.
How this page is built
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Surufatinib works or whether it is effective. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Surufatinib (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 10 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.